Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
25. Januar 2022 22:30 ET
|
NeuroSigma, Inc.
Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in ChinaInitial launch of Generation 1.0 device followed by Generation 1.5 device, to deploy in mainland...